Concepedia

Author

Joji Toyota

Sapporo Kosei General Hospital

Also Known As

Joji TOYOTA, Joji Toyota

63

Publications

3.2K

Citations

23

H-Index

44

Concepts

All Affiliations

Sapporo Kosei General HospitalToranomon HospitalHiroshima UniversityThe University of TokyoBristol-Myers Squibb (United States)
JT

About

Joji Toyota is an author at Sapporo Kosei General Hospital specializing in medicine, hepatitis, and viral hepatitis.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

14

16

1.5K

2

Health Sciences

3

3

267

3

Natural Sciences

1

1

229

4

Public Health

1

1

42

5

Cell Biology

1

1

229

Joji Toyota

×

36

Publications

3.2K

Citations

23

H-Index

YearCitations

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

Hiromitsu Kumada, Yoshiyuki Suzuki, Kenji Ikeda,

Hepatology

2014

538

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders

Kazuaki Chayama, Shoichi Takahashi, Joji Toyota,

Hepatology

2011

335

Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan

Hiromitsu Kumada, Joji Toyota, Takeshi Okanoue,

Journal of Hepatology

2011

252

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options

Yoshiyuki Suzuki, Kenji Ikeda, Fumitaka Suzuki,

Journal of Hepatology

2012

235

Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 σ gene in human hepatocellular carcinoma

Norikazu Iwata, Hiroyuki Yamamoto, Shigeru Sasaki,

Oncogene

2000

229

Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers

Daiki Miki, Hidenori Ochi, C. Nelson Hayes,

Nature Genetics

2011

170

Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir

Yoshiyasu Karino, Joji Toyota, Kenji Ikeda,

Journal of Hepatology

2012

165

Effect of vitamin K2 on the recurrence of hepatocellular carcinoma

Haruhiko Yoshida, Yasushi Shiratori, Masatoshi Kudo,

Hepatology

2011

126

IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C

Kazuaki Chayama, C. Nelson Hayes, Hiromi Abe,

The Journal of Infectious Diseases

2011

116

Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan

Hiromitsu Kumada, Takeshi Okanoue, Morikazu Onji,

Hepatology Research

2010

111

Page 1